このエントリーをはてなブックマークに追加
ID 59983
フルテキストURL
著者
Tsukioki, Takahiro Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Shien, Tadahiko Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID Kaken ID publons
Tanaka, Takehiro Department of Pathology, Okayama University Hospital Kaken ID
Suzuki, Yoko Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID
Kajihara, Yukiko Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Hatono, Minami Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kawada, Kengo Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kochi, Mariko Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Iwamoto, Takayuki Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Kaken ID researchmap
Ikeda, Hirokuni Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Taira, Naruto Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Kaken ID
Doihara, Hiroyoshi Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Toyooka, Shinichi Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID Kaken ID researchmap
抄録
Purpose
Metformin has been suggested to possibly reduce cancer risk. However, the mechanism underlying the positive effects of metformin on cancer treatment remains unclear. We conducted a prospective study to evaluate the effects of preoperative metformin in patients with early breast cancer.
Method
We evaluated the effects on immunological factors (TILs, CD4 + , CD8 + , PD-L1, IFNγ and IL-2) by comparing core needle biopsies (CNB) obtained before metformin treatment with surgical specimens. Seventeen patients were enrolled in this prospective study from January to December 2016. We also analyzed 59 patients undergoing surgery during the same period to reveal the correlation of immune factors between CNB and surgical specimen.
Result
There was a moderate correlation between CNB and surgical specimens on TILs and CD8 + lymphocyte. (TILs Rs = 0.63, CD4 + Rs = 0.224, CD8 + Rs = 0.42) In the metformin group, TILs increases were confirmed in five (29%) patients, while a decrease was confirmed in two (12%). The expressions of CD4 + and CD8 + by TILs were increased in 41% and 18% of surgical specimens, respectively. However, TILs number (p = 0.0554), CD4+ (p = 0.0613) and CD8 + (p = 0.0646) expressions did not significantly increased. Furthermore, IFNγ expression appeared to be increased in response to metformin (p = 0.08).
Conclusion
Preoperative metformin tends to increase TILs, as well as the numbers of CD4 and CD8 positive lymphocytes, and IFNγ levels. Metformin might improve immune function and have a possibility of chemo-sensitivity and thereby increase the effectiveness of immunotherapy, based on the results of this preliminary study.
キーワード
Breast cancer
Metformin
Preoperative
Tils
CD8
PD-L1
発行日
2020-06-12
出版物タイトル
Cancer Chemotherapy and Pharmacology
86巻
86巻
1号
1号
出版者
Springer
開始ページ
55
55
終了ページ
63
63
ISSN
0344-5704
NCID
AA00598397
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
©Author(s)
論文のバージョン
Publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1007/s00280-020-04092-2
ライセンス
http://creativecommons.org/licenses/by/4.0/
助成機関名
Japan Agency for Medical Research and Development
助成番号
19ck0106307h0003